vs

Side-by-side financial comparison of CUMBERLAND PHARMACEUTICALS INC (CPIX) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.

CUMBERLAND PHARMACEUTICALS INC is the larger business by last-quarter revenue ($13.7M vs $13.3M, roughly 1.0× OCULAR THERAPEUTIX, INC). CUMBERLAND PHARMACEUTICALS INC runs the higher net margin — -10.3% vs -488.0%, a 477.6% gap on every dollar of revenue. On growth, CUMBERLAND PHARMACEUTICALS INC posted the faster year-over-year revenue change (31.1% vs -22.4%). CUMBERLAND PHARMACEUTICALS INC produced more free cash flow last quarter ($3.0K vs $-57.1M). Over the past eight quarters, CUMBERLAND PHARMACEUTICALS INC's revenue compounded faster (26.9% CAGR vs -5.3%).

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded prescription medicines. Its core product portfolio covers acute care, gastroenterology, pain management and rare disease treatment, with its primary operating market being the United States, serving healthcare providers and patients in relevant care segments.

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

CPIX vs OCUL — Head-to-Head

Bigger by revenue
CPIX
CPIX
1.0× larger
CPIX
$13.7M
$13.3M
OCUL
Growing faster (revenue YoY)
CPIX
CPIX
+53.5% gap
CPIX
31.1%
-22.4%
OCUL
Higher net margin
CPIX
CPIX
477.6% more per $
CPIX
-10.3%
-488.0%
OCUL
More free cash flow
CPIX
CPIX
$57.1M more FCF
CPIX
$3.0K
$-57.1M
OCUL
Faster 2-yr revenue CAGR
CPIX
CPIX
Annualised
CPIX
26.9%
-5.3%
OCUL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CPIX
CPIX
OCUL
OCUL
Revenue
$13.7M
$13.3M
Net Profit
$-1.4M
$-64.7M
Gross Margin
83.6%
88.0%
Operating Margin
-10.0%
-526.5%
Net Margin
-10.3%
-488.0%
Revenue YoY
31.1%
-22.4%
Net Profit YoY
25.8%
-33.6%
EPS (diluted)
$-0.09
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPIX
CPIX
OCUL
OCUL
Q4 25
$13.7M
$13.3M
Q3 25
$8.3M
$14.5M
Q2 25
$10.8M
$13.5M
Q1 25
$11.7M
$10.7M
Q4 24
$10.4M
$17.1M
Q3 24
$9.1M
$15.4M
Q2 24
$9.8M
$16.4M
Q1 24
$8.5M
$14.8M
Net Profit
CPIX
CPIX
OCUL
OCUL
Q4 25
$-1.4M
$-64.7M
Q3 25
$-1.9M
$-69.4M
Q2 25
$-740.7K
$-67.8M
Q1 25
$1.3M
$-64.1M
Q4 24
$-1.9M
$-48.4M
Q3 24
$-1.5M
$-36.5M
Q2 24
$-1.1M
$-43.8M
Q1 24
$-1.9M
$-64.8M
Gross Margin
CPIX
CPIX
OCUL
OCUL
Q4 25
83.6%
88.0%
Q3 25
88.1%
87.8%
Q2 25
81.4%
85.6%
Q1 25
87.8%
88.2%
Q4 24
81.1%
92.8%
Q3 24
85.4%
89.9%
Q2 24
82.6%
90.8%
Q1 24
81.5%
91.0%
Operating Margin
CPIX
CPIX
OCUL
OCUL
Q4 25
-10.0%
-526.5%
Q3 25
-23.7%
-472.3%
Q2 25
-6.9%
-502.6%
Q1 25
11.0%
-597.5%
Q4 24
-17.7%
-296.1%
Q3 24
-18.6%
-298.2%
Q2 24
-10.4%
-265.1%
Q1 24
-22.0%
-214.0%
Net Margin
CPIX
CPIX
OCUL
OCUL
Q4 25
-10.3%
-488.0%
Q3 25
-23.4%
-477.3%
Q2 25
-6.8%
-503.9%
Q1 25
10.7%
-598.7%
Q4 24
-18.2%
-283.3%
Q3 24
-17.0%
-236.6%
Q2 24
-11.0%
-266.3%
Q1 24
-22.9%
-438.9%
EPS (diluted)
CPIX
CPIX
OCUL
OCUL
Q4 25
$-0.09
$-0.27
Q3 25
$-0.13
$-0.38
Q2 25
$-0.05
$-0.39
Q1 25
$0.08
$-0.38
Q4 24
$-0.13
$-0.25
Q3 24
$-0.11
$-0.22
Q2 24
$-0.08
$-0.26
Q1 24
$-0.14
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPIX
CPIX
OCUL
OCUL
Cash + ST InvestmentsLiquidity on hand
$11.4M
$737.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$24.9M
$654.3M
Total Assets
$76.8M
$808.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPIX
CPIX
OCUL
OCUL
Q4 25
$11.4M
$737.1M
Q3 25
$15.2M
$344.8M
Q2 25
$16.1M
$391.1M
Q1 25
$15.1M
$349.7M
Q4 24
$18.0M
$392.1M
Q3 24
$17.5M
$427.2M
Q2 24
$17.3M
$459.7M
Q1 24
$18.5M
$482.9M
Stockholders' Equity
CPIX
CPIX
OCUL
OCUL
Q4 25
$24.9M
$654.3M
Q3 25
$26.1M
$258.2M
Q2 25
$28.0M
$305.9M
Q1 25
$28.7M
$265.9M
Q4 24
$22.9M
$315.3M
Q3 24
$24.8M
$352.0M
Q2 24
$26.3M
$377.7M
Q1 24
$27.5M
$408.0M
Total Assets
CPIX
CPIX
OCUL
OCUL
Q4 25
$76.8M
$808.1M
Q3 25
$65.9M
$410.9M
Q2 25
$67.9M
$451.3M
Q1 25
$69.9M
$405.9M
Q4 24
$75.6M
$457.9M
Q3 24
$76.7M
$490.4M
Q2 24
$78.5M
$517.1M
Q1 24
$81.5M
$538.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPIX
CPIX
OCUL
OCUL
Operating Cash FlowLast quarter
$3.0K
$-54.2M
Free Cash FlowOCF − Capex
$3.0K
$-57.1M
FCF MarginFCF / Revenue
0.0%
-430.9%
Capex IntensityCapex / Revenue
0.0%
21.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.8M
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPIX
CPIX
OCUL
OCUL
Q4 25
$3.0K
$-54.2M
Q3 25
$187.2K
$-50.7M
Q2 25
$843.8K
$-55.2M
Q1 25
$3.9M
$-44.7M
Q4 24
$1.9M
$-39.4M
Q3 24
$475.5K
$-36.6M
Q2 24
$-855.7K
$-24.8M
Q1 24
$-2.1M
$-33.9M
Free Cash Flow
CPIX
CPIX
OCUL
OCUL
Q4 25
$3.0K
$-57.1M
Q3 25
$163.4K
$-56.7M
Q2 25
$817.3K
$-56.5M
Q1 25
$3.9M
$-46.6M
Q4 24
$1.9M
$-39.6M
Q3 24
$460.1K
$-36.6M
Q2 24
$-862.8K
$-25.5M
Q1 24
$-2.2M
$-34.1M
FCF Margin
CPIX
CPIX
OCUL
OCUL
Q4 25
0.0%
-430.9%
Q3 25
2.0%
-390.0%
Q2 25
7.5%
-419.7%
Q1 25
32.9%
-435.6%
Q4 24
18.2%
-232.0%
Q3 24
5.1%
-237.6%
Q2 24
-8.8%
-155.4%
Q1 24
-25.6%
-231.1%
Capex Intensity
CPIX
CPIX
OCUL
OCUL
Q4 25
0.0%
21.4%
Q3 25
0.3%
41.2%
Q2 25
0.2%
9.3%
Q1 25
0.4%
18.1%
Q4 24
0.0%
1.2%
Q3 24
0.2%
0.6%
Q2 24
0.1%
4.5%
Q1 24
0.5%
1.7%
Cash Conversion
CPIX
CPIX
OCUL
OCUL
Q4 25
Q3 25
Q2 25
Q1 25
3.10×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons